Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. [electronic resource]
Producer: 20070510Description: 538-40 p. digitalISSN:- 0007-1188
- 3',5'-Cyclic-GMP Phosphodiesterases -- antagonists & inhibitors
- Animals
- Antihypertensive Agents -- pharmacology
- Carbolines -- pharmacology
- Cardiomyopathies -- chemically induced
- Cardiovascular Agents -- pharmacology
- Cyclic Nucleotide Phosphodiesterases, Type 5
- Disease Models, Animal
- Doxorubicin
- Endothelium, Vascular -- drug effects
- Enzyme Inhibitors
- Erectile Dysfunction -- drug therapy
- Heart Failure -- drug therapy
- Humans
- Hypertension -- chemically induced
- Hypertension, Pulmonary -- drug therapy
- Imidazoles -- pharmacology
- Male
- Myocardial Infarction -- drug therapy
- Myocardial Reperfusion Injury -- chemically induced
- NG-Nitroarginine Methyl Ester
- Nitric Oxide -- metabolism
- Phosphodiesterase Inhibitors -- pharmacology
- Piperazines -- pharmacology
- Purines -- pharmacology
- Sildenafil Citrate
- Sulfones -- pharmacology
- Tadalafil
- Triazines -- pharmacology
- Vardenafil Dihydrochloride
- Vasodilator Agents -- pharmacology
- Ventricular Remodeling -- drug effects
No physical items for this record
Publication Type: Comment; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.